CANDUCCI, FILIPPO
 Distribuzione geografica
Continente #
NA - Nord America 6.289
EU - Europa 3.052
AS - Asia 1.885
SA - Sud America 122
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 4
Totale 11.382
Nazione #
US - Stati Uniti d'America 6.150
IT - Italia 1.672
SG - Singapore 621
UA - Ucraina 504
VN - Vietnam 327
TR - Turchia 317
CN - Cina 301
SE - Svezia 248
HK - Hong Kong 217
FI - Finlandia 134
DE - Germania 114
CA - Canada 110
BR - Brasile 96
FR - Francia 96
IE - Irlanda 92
GB - Regno Unito 82
RU - Federazione Russa 62
JP - Giappone 24
IN - India 23
MX - Messico 20
BD - Bangladesh 12
AR - Argentina 10
BE - Belgio 9
ES - Italia 9
EU - Europa 9
IQ - Iraq 9
NL - Olanda 9
PL - Polonia 8
ZA - Sudafrica 8
EC - Ecuador 6
ID - Indonesia 6
AT - Austria 5
LT - Lituania 4
CL - Cile 3
EG - Egitto 3
IL - Israele 3
KE - Kenya 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
KZ - Kazakistan 2
LB - Libano 2
MD - Moldavia 2
MY - Malesia 2
NG - Nigeria 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PE - Perù 2
PK - Pakistan 2
SA - Arabia Saudita 2
TT - Trinidad e Tobago 2
BH - Bahrain 1
BY - Bielorussia 1
BZ - Belize 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
GY - Guiana 1
HN - Honduras 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
KR - Corea 1
KW - Kuwait 1
MA - Marocco 1
NI - Nicaragua 1
OM - Oman 1
PH - Filippine 1
PS - Palestinian Territory 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 11.382
Città #
Milan 1.281
Fairfield 841
Woodbridge 508
Ashburn 496
Jacksonville 429
Houston 388
San Jose 382
Singapore 364
Chandler 350
Ann Arbor 313
Seattle 302
Cambridge 298
Wilmington 275
Hong Kong 213
Nyköping 163
Princeton 144
Izmir 141
Dearborn 137
Dallas 129
Boardman 113
The Dalles 110
Toronto 95
Dong Ket 93
Dublin 89
Beijing 81
Rome 73
Lauterbourg 62
Como 54
Council Bluffs 47
Hanoi 46
San Diego 46
Ho Chi Minh City 41
New York 24
Los Angeles 23
Tokyo 23
Chicago 21
Santa Clara 21
London 20
Nanjing 20
Ogden 20
Kunming 16
Hefei 15
Orem 14
Mexico City 13
Atlanta 12
Haiphong 11
São Paulo 11
Da Nang 10
Brussels 9
Munich 9
Washington 9
Chengdu 8
Chennai 8
Columbus 8
Denver 8
Guangzhou 8
Montreal 8
Verona 8
Warsaw 8
Brooklyn 7
Helsinki 7
Jinan 7
Mumbai 7
Norwalk 7
Nuremberg 7
Nanchang 6
Ponte Lambro 6
Baghdad 5
Hounslow 5
Johannesburg 5
Phoenix 5
Poplar 5
Guayaquil 4
Kilburn 4
Redmond 4
Salt Lake City 4
Wuhan 4
Amsterdam 3
Boston 3
Can Tho 3
Curitiba 3
Elk Grove Village 3
Fuzhou 3
Huzhou 3
Las Vegas 3
Nairobi 3
Phú Nhuận 3
Redwood City 3
Rio de Janeiro 3
San Francisco 3
Secaucus 3
Thủ Đức 3
Tübingen 3
Vienna 3
Abuja 2
Addis Ababa 2
Alexandria 2
Anápolis 2
Aparecida de Goiânia 2
Auckland 2
Totale 8.631
Nome #
Kuwanon-L as a New Allosteric HIV-1 Integrase Inhibitor: Molecular Modeling and Biological Evaluation 218
Duodenal mucosa of patients with type 1 diabetes shows distinctive inflammatory profile and microbiota 216
The Microbiome of the Prostate Tumor Microenvironment 213
One drug for two targets: Biological evaluation of antiretroviral agents endowed with antiproliferative activity 207
Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients. 206
Adaptive immunity against gut microbiota enhances apoE-mediated immune regulation and reduces atherosclerosis and western-diet-related inflammation 203
Cross-reacting antibacterial auto-antibodies are produced within coronary atherosclerotic plaques of acute coronary syndrome patients. 200
Inhibition of HIV-1 Reverse Transcriptase Dimerization by Small Molecules 198
Antigen-driven evolution of B lymphocytes in coronary atherosclerotic plaques. 195
Coronaviridae and SARS-associated coronavirus strain HSR1. 194
Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site. 181
Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection. 181
The interplay of extracellular matrix and microbiome in urothelial bladder cancer 181
Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. 180
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. 179
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL-authors' response 179
Immunological recovery after 24 weeks of antiretroviral therapy in patients with x4 virus during primary hiv infection 178
Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up 177
Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy. 177
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. 175
Natural Product Kuwanon-L Inhibits HIV-1 Replication through Multiple Target Binding 175
Integrase and fusion inhibitors transmitted drug resistance in naive patients with recent diagnosis of HIV-1 infection. 171
Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). 171
Epidemiological, molecular and clinical features of enterovirus 109 infection in children and in adult stem cell transplant recipients. 170
Efficacy of a multistep strategy for Helicobacter pylori eradication. 170
2-aminothiazolones as anti-HIV agents which act as gp120-CD4 Inhibitors 169
Helicobacter pylori treatment: a role for probiotics? 166
Onset of Berger disease after Staphylococcus aureus infection: septic arthritis after anterior cruciate ligament reconstruction. 165
Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. 165
Cloning and molecular characterization of a human recombinant IgG Fab binding to the Tat protein of human immunodeficiency virus type 1 (HIV-1) derived from the repertoire of a seronegative patient. 164
Oral probiotic VSL#3 prevents autoimmune diabetes by modulating microbiota and promoting indoleamine 2,3-dioxygenase-enriched tolerogenic intestinal environment 161
GB virus C and survival in persons with HIV infection 160
Probiotics and Helicobacter pylori eradication. 159
Quantitation of Bacillus clausii in biological samples by real-time polymerase chain reaction. 159
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. 159
Two-year prospective study of single infections and co-infections by respiratory syncytial virus and viruses identified recently in infants with acute respiratory disease. 157
HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients. 157
Revealing enterovirus infection in chronic human disorders: An integrated diagnostic approach 157
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. 156
Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression 156
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. 154
Pregnancy and H1N1 infection. 154
Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. 154
Persistent replication of severe acute respiratory syndrome coronavirus in human tubular kidney cells selects for adaptive mutations in the membrane protein. 154
Molecular epidemiology of KI and WU polyomaviruses in infants with acute respiratory disease and in adult hematopoietic stem cell transplant recipients. 153
Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. 152
In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir 152
The role of infections and coinfections with newly identified and emerging respiratory viruses in children. 152
Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure. 151
Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family 151
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. 149
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts. 148
Infection and coinfection of human rhinovirus C in stem cell transplant recipients. 147
IL28B rs12979860 genotype as a predictor marker of progression to BKVirus Associated nephropathy, after kidney transplantation 147
Comparison of the artus HIV-1 QS-RGQ and VERSANT HIV-1 RNA 1.0 assays for quantitative detection of human immunodeficiency virus type 1 in plasma samples 145
Rifabutin-based Helicobacter pylori eradication 'rescue therapy'. 142
A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments. 140
The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. 140
The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir. 136
Characterization of GBV-C infection in HIV-1 infected patients. 135
Quantitative HIV-1 proviral DNA detection: a multicentre analysis. 131
Heterogeneity of the humoral anti-HCV/E2 response in persistently infected patients as demonstrated by divergent patterns of inhibition of the binding of anti-HCV/E2 human monoclonal antibodies. 117
Phage display for the production of human monoclonal antibodies against human pathogens. 111
Humoral immune response against hepatitis C virus. 108
Sequence analysis of NS3 protease gene in clinical strains of hepatitis C virus. 106
Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV). 105
Helicobacter pylori: a culprit in extraintestinal diseases? 101
Phylogenetic internal control for HIV-1 genotypic antiretroviral testing. 100
Long-term study on symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. 98
Targeting patients' microbiota with probiotics and natural fibers in adults and children with constipation 96
Intra-host evolution of human immunodeficiency virus type 1 and viral fitness. 95
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. 93
TMEM219 signaling promotes intestinal stem cell death and exacerbates colitis 81
Totale 11.403
Categoria #
all - tutte 43.953
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.953


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021176 0 0 0 0 0 0 0 0 0 0 0 176
2021/2022655 81 141 5 53 8 21 41 42 33 82 66 82
2022/2023990 79 6 48 114 111 245 1 135 184 26 14 27
2023/20241.794 311 330 304 338 353 83 5 13 36 4 0 17
2024/2025701 1 1 151 5 6 77 65 18 25 54 64 234
2025/20262.129 187 133 96 248 211 109 446 117 299 157 101 25
Totale 11.403